| scholarly article | Q13442814 |
| P50 | author | Samuel Kuperman | Q56816772 |
| Janet A Schlechte | Q58365304 | ||
| Laura Acion | Q59211305 | ||
| Michael Tansey | Q61116906 | ||
| P2093 | author name string | Chadi A Calarge | |
| P2860 | cites work | The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents | Q22305963 |
| Variations in pattern of pubertal changes in girls | Q24569515 | ||
| Variations in the Pattern of Pubertal Changes in Boys | Q24569516 | ||
| From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase | Q24685521 | ||
| Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 | ||
| Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis | Q28237307 | ||
| Subclinical thyroid disease: scientific review and guidelines for diagnosis and management | Q28238612 | ||
| Evaluation of methods for the measurement of low-density lipoprotein cholesterol. | Q29547378 | ||
| Anthropometric reference data for children and adults: U.S. population, 1999-2002. | Q30994286 | ||
| Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds | Q33929303 | ||
| Body weight changes associated with psychopharmacology | Q34136794 | ||
| Consensus development conference on antipsychotic drugs and obesity and diabetes | Q34293049 | ||
| Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study | Q34945926 | ||
| Metabolic and body composition factors in subgroups of obesity: what do we know? | Q35794449 | ||
| The effects of antipsychotic therapy on serum lipids: a comprehensive review. | Q35832656 | ||
| Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment | Q36101507 | ||
| Acute and long-term safety and tolerability of risperidone in children with autism | Q36354271 | ||
| Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents | Q36532942 | ||
| The metabolic effects of antipsychotic medications | Q36577856 | ||
| The metabolic syndrome in children and adolescents - an IDF consensus report | Q36938565 | ||
| Defining the metabolic syndrome in children and adolescents: will the real definition please stand up? | Q37060936 | ||
| Natural history of beta-cell dysfunction in NIDDM. | Q37977228 | ||
| Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics | Q40193665 | ||
| Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine | Q44013107 | ||
| Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence | Q44086833 | ||
| Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. | Q44545460 | ||
| A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial | Q44635621 | ||
| Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. | Q45023301 | ||
| Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients | Q45193935 | ||
| The elucidation of the mechanism of weight gain and glucose tolerance abnormalities induced by chlorpromazine | Q47318134 | ||
| Signals that regulate food intake and energy homeostasis | Q48035240 | ||
| Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study. | Q51486823 | ||
| Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. | Q51679983 | ||
| National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. | Q51801492 | ||
| Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. | Q51899714 | ||
| Skinfold equations for estimation of body fatness in children and youth. | Q52551678 | ||
| Role of nonexercise activity thermogenesis in resistance to fat gain in humans. | Q55068194 | ||
| Centers for Disease Control and Prevention 2000 Growth Charts for the United States: Improvements to the 1977 National Center for Health Statistics Version | Q57196021 | ||
| Effects of Stimulant Medication on Growth Rates Across 3 Years in the MTA Follow-up | Q58822742 | ||
| The analysis of multiple endpoints in clinical trials | Q69417771 | ||
| Diagnosis and classification of diabetes mellitus | Q75205667 | ||
| Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability | Q83974157 | ||
| P433 | issue | 2 | |
| P921 | main subject | weight gain | Q3403879 |
| risperidone | Q412443 | ||
| teenager | Q1492760 | ||
| P304 | page(s) | 101-109 | |
| P577 | publication date | 2009-04-01 | |
| P1433 | published in | Journal of Child and Adolescent Psychopharmacology | Q15756086 |
| P1476 | title | Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents | |
| P478 | volume | 19 |
| Q37719385 | 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment |
| Q33755068 | A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys |
| Q38660754 | A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice |
| Q47242918 | A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients |
| Q54182516 | Advancing the Quality of Pediatric Antipsychotic Use: Maybe It Takes a PAL. |
| Q28287983 | Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability |
| Q40386583 | Antipsychotic prescribing for behavioral disorders in US youth: physician specialty, insurance coverage, and complex regimens |
| Q46668444 | Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine |
| Q45904529 | Attention to body mass index by child psychiatry providers when prescribing second-generation antipsychotic medication to children: a survey study using a clinical vignette. |
| Q37712697 | Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment |
| Q34613195 | Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents |
| Q49791275 | Chemical and non-chemical stressors affecting childhood obesity: a systematic scoping review |
| Q38266796 | Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder |
| Q38113748 | Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs |
| Q36373562 | Correlates of weight gain during long-term risperidone treatment in children and adolescents |
| Q58781420 | Does Melatonin and Melatonin Agonists Improve the Metabolic Side Effects of Atypical Antipsychotics?: A Systematic Review and Meta-analysis of Randomized Controlled Trials |
| Q35128405 | Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth |
| Q33845881 | First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents |
| Q36654483 | Impulsive Aggression as a Comorbidity of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents |
| Q36566387 | Iron Status in Toddlerhood Predicts Sensitivity to Psychostimulants in Children |
| Q36720726 | Iron deficiency in pediatric patients in long-term risperidone treatment |
| Q33694959 | Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality |
| Q34056408 | Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents |
| Q24610124 | Management of antipsychotic-related weight gain |
| Q34580449 | Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges |
| Q37247927 | Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents |
| Q34831800 | Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents |
| Q35763638 | Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice |
| Q36288272 | Rate of weight gain and cardiometabolic abnormalities in children and adolescents |
| Q43145177 | Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment |
| Q34413008 | Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene |
| Q89351758 | Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys |
| Q89483192 | Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization |
| Q51363558 | Ten years of antipsychotic prescribing to children: a Canadian population-based study. |
| Q93046594 | The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice |
| Q28394992 | The effect of psychostimulants on skeletal health in boys co-treated with risperidone |
| Q47302269 | The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study |
| Q35680962 | Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. |
| Q37236402 | Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents |
| Q38090490 | Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review |
Search more.